1



Board -2020 -Mtg -3-Evaluation Advisory Committee Chair Report


Section A: Introduction
? This report provides the Board with an overview of the activities of the
Evaluation Advisory Committee ( EAC ) since the December 2019 Board .
? Due to COVID -19 travel restrictions, the EAC had a virtual meeting on 25
March 2020 . Many items scheduled for the m eeting were postponed .
? Since the last report to the Board, the EAC has:
o Discussed novel evaluation methods in the face of COVID -19
impacting on traditional data collection approaches. The EAC
discussed the utility of a pulse survey to understand the impact of
COVID -19 on Routine Immunisation and that considerations and
questions around COVID -19 be considered as a part of ongoing
evalu ations ;
o Provided guidance on the draft questions for the final evaluation of
the A dvance Market Committment (AMC) ;
o App roved the addition of the Fragility, Emergencies , Refugees Policy
to the 2020 Evaluation Workplan ;
o Provide d guidance to the Secretari at on how to strengthen utility of
learning products and communication of evaluation findings ; and
o Provided detailed fee dback on the Terms of Reference ( ToR ) for the
evaluations of Gavi?s Engagement with the Private Sector and the
Supply and Procurement Strategy. Final reports are expected Q4
2020.
? The EAC will focus on the 2021 workplan and supporting Gavi to develop a
robust Theory of Change for Gavi 5.0 and an evaluation work plan which
reflects the impact of recent Gavi Alliance B oard decisions related to
COVID -19. This should include how COVID -19 programming affects Gavi ?s
other investments.
SUBJECT : EVALUATION ADVISORY COMMITTEE CHAIR REPORT
Category: For Information
Report to the Board
24 -25 June 2020

1



Board -2020 -Mtg -3-Governance Committee Chair Report

Section A: Introduction
? This report provides the Board with an overview of the activities of the
Governance Committee (GC) since the Board last met in December 2019 .
? The GC met virtually on 11 February 2020, 17 March 2020 and 30 April
2020 .
? In addition to some routine business su ch as B oard and Committee
nominations and the recruitment of Unaffiliated Board members, Committee
discussions focused on work in relation to the (i) Board Chair recruitment
process, (ii) organising principles for the Donor and Research and Technical
Healt h Institutes constituencies , (iii) Guiding Principles on Gender for Board
and Committee nominations , (iv) a mendments to the Secretariat Conflicts
of Interest Policy and (v) discussions related to revising the Gavi Statutes,
retiring the Gavi By -laws and replacing it with the new Board and Board
Committee Operating Procedures.
? The Board, at its meeting on 17 March 2020, already approved
amendments to the Gavi By -laws and Governance Commi ttee Charter on
the recommendation of the Governance Committee.
? In addition, a nomination for an Alternate Board member submitted to the
Governance Committee at its meeting on 30 April 2020 has already been
circulated to the Board for no objection consent .
? The GC will meet on 18 June 2020 a nd it is expected that further
recommendations will be put forward to the Board on the consent agenda
at its June meeting in relation to Board and Committee appointments,
Independent Review Committee appointments, appointment of a new
Secretary , amendments to the Gavi Statutes and approval of new Board
and Board Committee Operating Procedures .
? The GC Chair report is attached in the form of a presentation as Annex A .
Annexes
Annex A : Governance Committee Chair report
SUBJECT : GOVERNANCE COMMITTEE CHAIR REPORT
Category: For Information
Report to the Board
24-25 June 2020

1



Board -2020 -Mtg -3-Investment Committee Chair Report


Section A: Introduction

? This report provides the Board with a n overview of an extraordinary and
unprecedented period in financial markets, reviews investment performance
during this period and updates on the activities of the Investment
Committee . The Committee met twice in the first half of 2020.

? At the start of 2020, the economic backdrop was benign. Market consensus
was that the emerging coronavirus threat from Wuhan could be contained
within China. Effectively the virus was viewed as a human tragedy but not
a market moving event.

? Market panic then ensu ed in February and March as investors reali sed that
the C OVID -19 pandemic could not be contained without putting much of the
global economy into an induced coma. The intensity and volatility of the sell -
off left an indelible mark. The US S&P 500 equity in dex went from peak to
trough ( -34%) in 24 trading days. By comparison, during the 2008 Global
Financial Crisis, the S&P 500 took 356 trading days from peak to trough ( -
57%). While much of the media focus was on equity markets, extreme
market volatility spr ead into other asset classes, including commodities and
investment grade and high yield fixed income credit markets. Developed
market sovereign bonds benefitted from a flight to quality, but all risk assets
fell in unison and the benefits of asset class di versification temporarily
disappeared.

? Having reported a positive return of 12.4% in 2019, the long -term portfolio
suffered a drawdown of -10.6% in Q1 2020 at the height of the C OVID -19
panic. Since March month -end, the portfolio has meaningfully recov ered
such that the year -to -date loss at May month -end is a manageable -3.4 %.

? The drawdown in Q1 2020 was in line with the risk measures and scenarios
(Value at Risk) previously presented to the Board, but performance through
month -end March was nevert heless underwhelming. The Investment
Committee believed heading into the pandemic that markets were fully
valued and had added strategies to the portfolio that were only modestly or
in some cases negatively correlated with overall market volatility. These
included Long/Short equity allocations in the Equity sector and a Dispersion
SUBJECT: INVESTMENT COMMITTEE CHAIR REPORT
Agenda item: 4
Category: For Information
Report to the Board
24 -25 June 2020

1



Board -2019 -Mtg -3-Doc 07


Section A: Executive Summary
Context
Gavi has had a Gender Policy to guide its programmatic work since 2008 . The original
policy was updated in 2013 to the current version . The current policy has been
revised by the Secretariat following a review process which included an independent
external evaluation , analysis, and extensive consultation s with country
re presentatives, partners, civil society organisations, gender and immunisation
experts and donors. In May 2020, the Programme and Policy Committee (PPC)
recommended that the Board approve the revised Gender Policy , congratulating the
Secretariat on the highly consultative and inclusive review process.
Questions this paper addresses
? How has the Gender Policy been revised as a result of the review?
? What is the relevance of this policy to the COVID -19 pandemic?
Conclusions
Gavi?s Gender Policy aims to support Gavi?s bold aspiration of ?Leaving no one
behind with immunisation? and to strengthen vaccine programmes and health
systems to increase equity in imm unisation. The revisions seek to better align the
policy with Gavi?s strategy for 2021 -2025 (Gavi 5.0) . With equity as the organising
principle, it focuses on ensuring zero -dose and underimmunised children,
individuals and communities are sustainably reach ed with routine immunisation
services. The revised policy is more ambitious and identifies areas for gender -
responsive and transformative interventions, underpinned by an updated theory of
change which places a new focus on understanding, learning and part nering as
approaches to achieve the policy goals. It uses inclusive, non -binary language and
considers how other socio -cultural factors can compound gender -related barriers.
In addition to caregivers, the policy focuses on two new groups: healt h workers an d
adolescents, both of wh om face specific gender -related barriers to providing or
accessing healthcare.
The Secretariat is working closely with partners to better understand the gendered
impacts of the COVID -19 pandemic and proactively suggesting potential
approaches to addressing these challenges.
The Secretariat is presenting a revised Gender Policy to the Board for approval (see
Annex B).
SUBJECT : REVIEW OF THE GAVI GENDER POLICY
Agenda item: 07
Category: For Decision
Report to the Board
24 -25 June 20 20

1



Board -2020 -Mtg -3-Doc 08
Report to the Board
24 -25 June 20 20

















SUBJECT: REVIEW OF DECISIONS
Agenda item: 08
No paper

1



Board -2020 -Mtg -3-Doc 09
Report to the Board
24 -25 June 20 20

















SUBJECT: CLOSING REMARKS
Agenda item: 09
No paper

Report to the Board
Board -2020 -Mtg -3-Doc 06-Annex C
Annex C : Summary of Indicator Definitions 1
Table 1: Summary Descriptions and Use Cases for Mission Indicators
ID Indicator What would be measured How it would be used
M.1 Under -5 mortality rate
Average probability of a child
born in any of the Gavi -
supported countries dying
before they reach the age of
five.
Communicate Gavi?s
contribution to child mortality
reduction
M.2 Future deaths averted 2
Number of anticipated future
deaths prevented as a result of
vaccination with Gavi -funded
vaccines in the countries we
support
Demonstrate Gavi impact on
vaccine preventable disease
(VPD) mortality.
M.3 Future DALYs averted
Number of disability -adjusted
life years (DALYs) averted as a
result of vaccination with Gavi -
supported vaccines.
Demonstrate Gavi impact on
VPD mortality and morbidity.
M.4 Zero -dose children
(Equity indicator)
Reduction in number of zero -
dose children
Measure of extending routine
immunisation services to
missed communities. An
equity measure.
M.5
Unique children
immunised with Gavi
support
Number of children immunised
with the last recommended
dose of a Gavi -supported
vaccine delivered through
routine systems
Demonstrate reach of Gavi
support.
M. 6 Economic benefits
unlocked
Calculated as cost -of-illness
(COI) averted. COI includes
treatment and transport costs,
caretaker wages and
productivity loss due to
disability and premature death.
Demonstrate Gavi impact on
economic productivity.






1 Indicators for strategy goal 3 have yet to be defined. Measurement of SG3 pending Alliance
discussions on financing and Board decision on the updated eligibility, transition and co -financing policy. 2 Indicators underlined are included in the 2020 -2025 I nvestment Opportunity and will be used, in part,
to report on progress towards meeting commitments made in 2021 -2025 Investment opportunity.

1



Board -2020 -Mtg -3-Doc 06


Section A: Executive Summary
Purpose of the report
Following discussion s at the October 2019 and May 2020 Programme and Policy
Committee (PPC) meetings , the Board is requested to provide guidance on the
Gavi 5.0 measurement framework. An Alliance Technical Working Group (TWG)
is advising on development of the framework and e nsuring alignment with
Immunization Agenda 2030 (IA2030). An iterative process with broad consultations
to vet indicators has included consultations with countries, partners, Civil Society
Organisations and other Alliance stakeholders at the Gavi 5.0 Count ries and
Partners Retreat.
Questions this paper addresses
? How is the 5.0 measurement framework being developed?
? Which indicators are currently suggested for 5.0 strategy performance
monitoring, at which levels, and which require further development?
? How do es the COVID -19 pandemic affect finalisation of the 5.0
measurement framework?
The COVID -19 pandemic will delay finalisation of the 5.0 measurement framework,
largely due to the challenge of setting targets given uncertain 2020 baselines .
Section B: Gavi 5.0: Measurement Framework/Strategy Indicators
Facts and Data
1.1 Proposed Gavi 5.0 mission and strategy indicators are intended to measure
progress towards the goals and objectives as described in the Gavi 5.0
strategy framework ?one -pager? ( Annex A), approved by the Board in June
2019 . They focus on key portfolio -level impacts, outcomes or outputs , with
shared accountability across the Alliance . They represent a subset of the
metrics to be used for monitoring progress along Gavi?s result chai n.
1.2 The following principles guide the development of Strategy Performance
Monitoring (details provided in Doc 06 to the October 2019 PPC meeting):
SUBJECT : GAVI 5.0: MEASUREMENT FRAMEWORK/STRATEGY
INDICATORS
Agenda item: 06
Category: For Guidance
Report to the Board
24 -25 June 2020

Report to the Board
Board -2020 -Mtg -3-Doc 07-Annex A
Annex A: Implications
? Risk implication and mitigation, including information on the risks of
inaction . Gender has been identified as an important determinant of health and
immunisation outcomes . Inaction would result in Gavi not being able to reach
as many zero -dose and underimmunised children . ?G ender -focus? has been
elevated to a principle in Gavi 5.0, key to achieving the vision , so this policy
update is necessary to ensure Gavi programming is fit for purpose.
? Impact on countries. Gavi -supported c ountries will require support to identify
and address gender -related barriers. The 5.0 vision and this policy raise the
priority level of gender within the context of equity and countries will be
encouraged to programme their health system strengthening funding to find and
reach zero -dose and underimmunised children, an important part of which is
addressing gender considerations.
? Impact on Alliance. As a cross -cutting policy, the success of implementation
will be driven in large part by Alliance partners who will play an integral role in
supporting achievement of the policy objectives. A deliverable of the policy is
to ?Partner? effectively , which includes mainstreaming gender throughout the
Alliance to ensure alignment on goals regarding gender. Implementation of
more gender -focused activities will be supported through Gavi?s different
funding channels and through its engagement with partners.
? Legal and governance implications. There are no legal implications with
respec t to the content of this report. The gender balance of governance
structures has been reviewed alongside the policy review and can be found in
Doc 01f .

Report to the Board

Board -2020 -Mtg -3-Doc 07-Annex B

Annex B: Revised Gender Policy






DOCUMENT ADMINISTRATION
VERSION
NUMBER APPROVAL PROCESS DATE
3.0 Reviewed by: Programme and Policy
Committee
2.0 ? 10 October 2013
3.0 ? 26 May 2020
Approved by: Gavi Alliance Board

1.0 ? 26 June 2008
Effective from 1 July 2008
2.0 ? 21 November 2013
Effective from 1 January 2014
3.0 ? 24 June 2020
Effective from: 1 July 2020
Next review: At the request of the Board
Gavi , the Vaccine Alliance
Gender Policy
Version 3.


Report to the Board
Board -2020 -Mtg -3-Doc 07-Annex B
2
Definitions
o Zero -dose children are those who have not receive d any routine vaccine. For
operational purposes, Gavi measures zero -dose children as those who have not
received their first dose of diphtheria -tetanus -pertussis containing vaccine (DTP1).
o Under immunised individuals include children, adolescents and adults that are
missing their full course of vaccination.
o Caregiver is a person who regularly or intermittently cares for an infant or child.
Examples include mothers, fathers, grandparents and siblings .
o Sex refers to the biological characteristics that define humans as female, male or
intersex and is typically assigned at birth.
o Gender is about the roles, norms and behaviours that society consider s appropriate
for women, men, girls, boys, and those with diverse gender identities , such as
transgender . These are socially constructed , fluid , and var y widely within and across
time, cultures, religions, class and ethnicity.
o Gender -related barrier s are related to deep rooted social and cultural norms about
the roles of women, men , and those with diverse gender identities , that create
obstacles to equitable access and use of health services . For example, when
caregivers, primarily women , have not completed secondary educat ion , lack decision -
making power, or are unable to move freely outside their homes, there is a greater
likelihood that they will not take their children to get vaccinated . In addition, lack of
male en gagement can contribute to poor child health outcomes .
o Intersectionali ty refers to the overlap between multiple forms of inequality or
discrimination which create obstacles for individuals, for example, access and use of
health services. Gender identity can intersect with additional factors, including but not
limited to age, geographical location, education, ethnicity, religion, class,
socioeconomic status, disability, migration/refugee status, sexual orientation.
o Gender equity is the process of being f air to women , men and those with diverse
gender identitie s. It recogniz es that individual s of different gender identities have
different needs, power and access to resources, which should be identified and
addressed to rectif y the imbalance . Addressing gender e quity leads to equality .
o Gender equality is the absence of discrimination based on a person?s sex or gender
identity . It means ensuring that the same opportunity is accessible to each person such
as access to and control of social, economic and political resources, including
protection under the law ( e.g. , health services, education and voting rights).
o Gender -responsive approaches adopt a gender lens to consider individual needs of
different gender identities without necessarily chang ing the larger contextual issues
that lie at the root of the gender inequities and inequalities . For example, employing
female health workers will facilitate enhance d immunisation service acceptance and
uptake, but would not address the underlying cultural barrier that prevents female
caregivers from seeking immunisation services from male health workers.
o Gender -transformative approaches are those that attempt to re -define and change
existing gender roles , norms, attitudes and practices. These interventions tackle the
root cause s of gender inequity and inequality and reshape unequal power relations.

Report to the Board
Board -2020 -Mtg -3-Doc 07-Annex C

Classified as Internal
Annex C: Gender Policy Monitoring and Evaluation Framework

Theory of Change

Report to the Board
2
Board -2020 -Mtg -3-Doc 07-Annex C
Classified as Internal
Monitoring Framework
The implementation and adherence to the Gender Policy will be monitored by the Gavi Secretariat
on an ongoing basis. This policy also points to the need for better data to be able to assess the
need for, and progress of, interventions to tackle gender -related barriers. The implementation of
the policy will be monitored at the strategic, process and country -levels. With the implementation
of Gavi?s new strategy beginning in 2021 these indicators and monitoring processes are subject
to ev olution and addition.
Strategy -level
Gavi?s strategy for 2021 -2025 (Gavi 5.0) includes a principle around ?gender -focus?. Monitoring of
gender -related performance will sit under Strategic Goal 2: Strengthen health systems to increase
equity in immunisatio n. The specifics will be detailed in strategic implementation monitoring
documents.
Process -level
Gavi?s progress in implementing the policy will be monitored through process -level indicators on
an annual basis, where possible. These process -level indicat ors map to the six deliverables
articulated in the Policy and theory of change and will be monitored at an aggregate level across
countries or Alliance partners, and not at individual country or partner level. As gender -related
barriers are highly context specific, outcomes will not be monitored at aggregate level but rather
country by country, as described in the following section. The process -level indicators will be
refined and finalised alongside the new strategy, and include, but not be limited to, tra cking the
following activities:
Understand
? Number of people trained in gender with Gavi funds (disaggregated by place of work:
Gavi Secretariat, Alliance partner, country EPI programme)
? % of teams mainstreaming gender into their processes and deliverables
Advocate
? Number of priority public policy outcomes for which Gavi has driven inclusion of gender
language and positioning (at global, regional and country levels)
? % of countries that include gender -related activities in their National Immunisa tion Strategies
Identify
? % of countries demonstrating that they have assessed gender -related barriers to
accessing immunisation services as part of their broader analysis of barriers to reaching
zero dose (using for example, equity assessment, gender situa tional reports)
Reach
? % of countries prioritising at least one intervention to tackle gender -related barriers
? % of countries budgeting for at least one intervention to tackle gender -related barriers
? % of countries tracking their progress in tackling gend er-related barriers with at least one
context -relevant indicator
? % of HPV support applications that plan for integrated services for adolescents

Report to the Board
Board -2020 -Mtg -3-Doc 06-Annex A

Annex A: Gavi 2021 ?2025 Strategy Fr amework